Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bright Minds Biosciences Inc. (DRUG : NSDQ)

• Company Description    Bright Minds Biosciences is a biotechnology company. It focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain. Bright Minds Biosciences is based in VANCOUVER, British Columbia. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.89 Daily Weekly Monthly 20 Day Moving Average: 48,762 shares Shares Outstanding: 11.85 (millions) Market Capitalization: $10.60 (millions) Beta: 52 Week High: $8.95 52 Week Low: $0.76 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -27.82% -18.71% 12 Week -59.68% -55.68% Year To Date -71.77% -62.11%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 19 VESTRY STREET - NEW YORK,NY 10013 USA ph: 64-7407-2515 fax: - None https://brightmindsbio.com

• General Corporate Information    Officers Ian McDonald - President; Chief Executive Officer and Director Ryan Cheung - Chief Financial Officer Gideon Shapiro - Vice President Nils Christian Bottler - Director Jeremy Fryzuk - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 10919W108 SIC: 2834 Fiscal Year Fiscal Year End: September Last Reported Quarter: 03/01/22 Next Expected EPS Date: - Share - Related Items Shares Outstanding: 11.85 Most Recent Split Date: (:1) Beta: Market Capitalization: $10.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.25 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - - 12/31/21 - - 09/30/21 - - Current Ratio 03/31/22 - 11.73 12/31/21 - 31.51 09/30/21 - 31.41 Quick Ratio 03/31/22 - - 12/31/21 - 31.52 09/30/21 - 31.41 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 0.72 12/31/21 - 1.00 09/30/21 - - Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©